Drug intelligence / Profile preview

GLS-8100

Development stage: Preclinical
Lead developer: GeneOne Life Science

Overview

GLS-8100 is a drug candidate under development by GeneOne Life Science for the treatment of rheumatoid arthritis. It is part of the company's discovery and optimization stage pipeline, indicating it is in early preclinical or research phases. Specific details about its mechanism of action, modality, or molecular target have not been disclosed publicly as of June 2025. The drug does not appear to be a combination product or biosimilar/generic formulation.

Beyond the preview

Go deeper on GLS-8100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLS-8100.

Explore the full profile